Profusa wins $1.75m NIH grant for tissue-integrated biosensors

San Francisco-based tissue-integrated sensor maker Profusa said today it won a $1.75 million grant from the National Institutes of Health’s Small Business Innovation Research program. Funding is slated to help support the company’s fast-tracked Phase I and Phase II studies of its Lumee tissue-integrated biosensors designed for continuous oxygen monitoring to improve outcomes in patients with peripheral artery disease. “This NIH award is further validation of the potential of our biosensor technology for having a significant impact in transforming clinical outcomes for patients with PAD. These studies will be crucial in advancing our technology and products towards regulatory approvals and commercialization,” CEO Ben Hwang said in a press release. Phase I of the grant will fund safety studies of Lumee, Profusa said, and Phase II is slated to fund a clinical study of the company’s tech at the University of California San Francisco. Profusa said the grant is the 2nd fast-track small business grant it has received from the NHLBI to develop its tissue-integrated oxygen biosensor for PAD patients. “Our goal is to further demonstrate the functionality of Profusa’s novel Lumee oxygen biosensor technology in patients with PAD, and to determine its ability to predict surgical outcomes and to guide additional therapies to avoid amputation,” CTO and study co-principal investigator Natalie Wisniewski said in a prepared statement. The Phas...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Diagnostics Profusa Source Type: news